StemCell Therapy

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.

The week was light on news flow, barring some smid-cap earnings andCOVID-19 treatment and vaccine news.

The following arekey catalysts in the unfolding week that a biotech investor should stay tuned to.

Barclays Global Healthcare Conference: March 10-12 in Miami, Florida.American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.

The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE: BMY) sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.

Blueprint Medicines Corp (NASDAQ: BPMC) is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.

See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Monday

Tuesday

Wednesday

Friday

Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."

Revolution Medicines Inc (NASDAQ: RVMD)

Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original post:
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues - Benzinga

This entry was posted on March 12, 2020 at 8:50 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |